Download the full report
In this free report, you'll learn:
- The industry’s top infrastructure priorities for patient access.
- How you need to work with regulators to accelerate innovation.
- Strengthen your hand with investors by showing readiness for scale-up.
- Design outperforming partnerships to support automation, customisation and cost reduction.
- Explore the skills needs of the future workforce and policy support to boost manufacturing expansion.
Executive summary
The 4th Cell and Gene Therapy Exchange 2025 brought together leading international stakeholders from across the industry to discuss the manufacturing challenges that come with expansion into indications such as solid cancers, autoimmune and other common conditions.
As organisers of the event, we at TTP have distilled the day’s discussions into 11 recommendations, summarised together with the day’s discussions in this report, to support executives, and the industry as a whole, on their journey to commercial scale. Organised into Infrastructure, Regulation, Technology, Funding and Policy, these priorities emphasise the importance of collaboration in order to meet future patient demand.
Collaboration with healthcare-focused organisations will be required to support patient access, and with regulators in view of the pace of innovation. Automation and digitalisation are critical to reach five-digit manufacturing volumes. Cell therapy developers therefore need to work with equipment and technology suppliers to demonstrate commercialisation readiness to investors. Governments could provide further industry-tailored support for clinical trials and training as cell therapy manufacturing shifts from manual to digital.
In some areas, the collaboration to meet future patient demand may need to be industry-wide, for example with respect to translational challenges, standardising upstream inputs, or research into stabilisation techniques for delicate materials to support manufacturing at scale.
The Exchange was hosted by the British Embassy, Berne and organised by independent technology and product development organisation TTP with it’s spin-out company Cellular Origins under the UK-Swiss innovation cooperation agreement.
We at TTP want to encourage cell therapy industry leaders to align on the recommendations in this report to enable collective progress to be made.
Acknowledgements
We would like to extend our sincere thanks to those who generously shared their time and expertise in reviewing this report.
From outside our organisation, we are especially grateful to Steven Howe (VP Process Development, Resolution Therapeutics), Sarah de la Mota (Business Development, Limula), and Jason Jones (Head of Global Business Development, Cellular Origins) for their thoughtful feedback and industry perspectives. We would like to extend out thanks to the team at the British Embassy, Berne for their support and coordination of the event. We are also grateful to Biopôle, Lausanne for generously providing us with a venue for the event.
We would also like to acknowledge our colleagues within the Advanced Therapies team. Stuart Lowe (Head of Advanced Therapies) and Elena Boland (Molecular Biologist and Virologist) provided invaluable input and constructive review.
In addition, we would like to thank everyone who attended and contributed to the 4th UK/Swiss Cell and Gene Therapy Event in June 2025. The open exchange of expertise and perspectives at this gathering underscored just how important collaboration is for the sector. Bringing leaders together in this way is vital to ensure the industry continues to move forward quickly and effectively to accelerate progress for patients.
